Skip to Content
MilliporeSigma
  • Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

Current drug metabolism (2005-10-27)
E Fontana, P M Dansette, S M Poli
ABSTRACT

The inhibition of human cytochrome P450s (CYPs) is one of the most common mechanisms which can lead to drug-drug interactions. The inhibition of CYPs can be reversible (competitive or non-competitive) or irreversible. Irreversible inhibition usually derives from activation of a drug by CYPs into a reactive metabolite, which tightly binds to the enzyme active site, leading to a long lasting inactivation. This process is called "mechanism based inhibition" or "suicide inhibition". The irreversible inactivation usually implies the formation of a covalent bond between the metabolite and the enzyme, which can lead to hapten formation and can in some cases trigger an autoimmune-response. For these reasons it is of utmost importance to study the mechanism of the CYP inhibition of new potential drugs as early as possible during the drug discovery process. The literature on CYPs is vast and covers numerous aspects of their biology and biochemistry, however to our knowledge there is no general and systematic review focusing on mechanism-based inhibitors; we have reviewed the literature and compiled all the available data on chemical entities, which are known to be CYP suicide inhibitors. Each compound is reported together with its chemical structure, the CYP isoform and the parameters describing the inactivation. Literature references are reported together with their PMID (PubMed ID number) to allow a fast retrieval of the papers. This review offers a quick reference to help predict liabilities of new chemical entities without carrying out extensive in vitro work, and will hopefully help in designing safer drugs.

MATERIALS
Product Number
Brand
Product Description

Supelco
Methimazole, analytical standard
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
17α-Ethynylestradiol, ≥98%
Sigma-Aldrich
Capsaicin, ≥95%, from Capsicum sp.
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
2-Propylpentanoic acid
Sigma-Aldrich
Psoralen, ≥99% (HPLC)
Sigma-Aldrich
Phenethyl isothiocyanate, 99%
Sigma-Aldrich
Capsaicin, from Capsicum sp., ≥50% (HPLC)
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Supelco
Trichloroethylene, analytical standard, stabilized with 30 – 50 ppm Diisopropylamine
Supelco
(−)-Nicotine, PESTANAL®, analytical standard
Sigma-Aldrich
Capsaicin, natural
Sigma-Aldrich
5-Methoxypsoralen, 99%
Sigma-Aldrich
2-Mercapto-1-methylimidazole, ≥99%
Sigma-Aldrich
Benzyl isothiocyanate, 98%
Sigma-Aldrich
Trichloroethylene, anhydrous, contains 40 ppm diisopropylamine as stabilizer, ≥99%
Supelco
(−)-Nicotine solution, 1.0 mg/mL, analytical standard, for drug analysis
Sigma-Aldrich
(−)-Nicotine, ≥99% (GC), liquid
Sigma-Aldrich
Trichloroethylene, ACS reagent, ≥99.5%
Supelco
Resveratrol, analytical standard
Sigma-Aldrich
3,3-Dimethyl-1-butyne, 98%
Sigma-Aldrich
tert-Butyl isothiocyanate, 99%
Sigma-Aldrich
α-Naphthoflavone, ≥98%
Supelco
Isoniazid, analytical standard, ≥99% (TLC)
Sigma-Aldrich
2-Bromo-2-chloro-1,1,1-trifluoroethane, ≥99%
Supelco
8-Methoxypsoralen, analytical standard